CATHVISION ApS
Nøgletal
- Afkastningsgrad
- -37,1 %
- Egenkapitalforrentning
- -45,1 %
- Likviditetsgrad
- 226 %
- Soliditetsgrad
- 78,6 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | -13.538.371 |
Driftsresultat | -37.764.008 |
Finansielle indtægter | 14.238 |
Finansielle omkostninger | 628.107 |
Skat af årets resultat | -2.241.864 |
Årets resultat | -36.136.013 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 13 |
Personaleomkostninger | 12.332.253 kr. |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 13.489.288 |
Kortfristede aktiver | 18.120.740 |
Langfristede aktiver | 83.768.906 |
Aktiver i alt | 101.889.646 |
Egenkapital | 80.093.733 |
Forpligtelser i alt | 21.795.913 |
Kortfristede forpligtelser | 8.019.440 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Varebeholdninger | 1.313.179 |
Andre kortfristede tilgodehavender | 650.055 |
Leverandørgæld | 1.243.878 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 948.454 |
Overført resultat | 14.257.270 |
Investeringer og aktiver
| Regnskabsperiode | |
|---|---|
Langfristede investeringer og tilgodehavender | 459.910 |
Materielle anlægsaktiver | 119.241 |
Højdepunkter fra årsrapporten
Forretning og udvikling
The Company operates within the medical technology sector and is engaged in the development and commercialization of advanced electrophysiology solutions. Its activities primarily comprise the design and development of technology for measuring and analysing cardiac electrical signals, including proprietary electrophysiology recording systems and AI-based analytical software used in the diagnosis and treatment of cardiac arrhythmias.
The Company’s solutions are intended for use by electrophysiologists and hospitals, supporting clinical decision-making and improving patient outcomes through enhanced signal acquisition, analysis and interpretation.…
The income statement for 2025 shows a loss of DKK 36,136,013 against a loss of DKK 38,766,109 last year, and the balance sheet at 31 December 2025 shows equity of DKK 80,093,733.
Going concernThe Company monitors its funding position on a monthly basis to ensure that it has access to sufficient funds to meet its forecasted cash requirement. This includes investing in research and clinical programs for the pipeline. Analyses are run to reflect different scenarios including, but not limited to, cash runway, human capital resources and pipeline priorities in order to identify risks to future liquidity and to enable Management to take corrective actions and allow the Company to continue as a going concern.…
Risici og væsentlige forhold
The Company monitors its funding position on a monthly basis to ensure that it has access to sufficient funds to meet its forecasted cash requirement. This includes investing in research and clinical programs for the pipeline. Analyses are run to reflect different scenarios including, but not limited to, cash runway, human capital resources and pipeline priorities in order to identify risks to future liquidity and to enable Management to take corrective actions and allow the Company to continue as a going concern.
During the year, the Company completed capital increases totaling DKK 27,556 thousand. Transaction costs related to capital increases, DKK 305 thousand are recognized directly in equity through retained earnings.…
Subsequent to the balance sheet date, the Company received loan financing of EUR 2.6 million provided
by existing shareholders.
No other events materially affecting the Company's financial position have occurred subsequent to the financial year-end.
Forpligtelser og sikkerhedsstillelser
Other contingent liabilities
The company has entered into lease rental property, which can be terminated by 6 months notice. The Company has rental commitments for a total of DKK 1,131 thousand on the current lease rental property.
The Company has not provided any security or other collateral in assets at 31 December 2025.
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger